Patents by Inventor Christine Rouzioux
Christine Rouzioux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11459623Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consistingType: GrantFiled: May 4, 2018Date of Patent: October 4, 2022Assignees: UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CHU DE ROUEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, UNIVERSITÉ PARIS NORDInventors: Adeline Melard, Mélanie Bertine, Véronique Avettand Fenoel, Florence Damond, Christine Rouzioux, Diane Descamps, Marie Gueudin, Jean-Christophe Plantier
-
Publication number: 20200080160Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complementary of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary of these sequences, and a set comprising a primer comprising or coType: ApplicationFiled: May 4, 2018Publication date: March 12, 2020Inventors: Adeline MELARD, Mélanie BERTINE, Véronique AVETTAND FENOEL, Florence DAMOND, Christine ROUZIOUX, Diane DESCAMPS, Marie GUEUDIN, Jean-Christophe PLANTIER
-
Patent number: 10385410Abstract: The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO 1, and sequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, and sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, and sequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, and (ii) at least 2 labelled probes respectively comprising or consisting of: sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, and sequence SEQ ID NO: 6, a sequence complemenType: GrantFiled: May 27, 2015Date of Patent: August 20, 2019Assignees: UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CHU DE ROUEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, UNIVERSITE PARIS DIDEROTInventors: Christine Rouzioux, Jean-Christophe Plantier, Véronique Avettand-Fenoel, Florence Damond, Marie Gueudin, Diane Descamps
-
Publication number: 20170218467Abstract: The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: —sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a nd—sequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, a nd—sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a nd—sequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, a nd (ii) at least 2 labelled probes respectively comprising or consisting of:—sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, and—sequence SEQ ID NO: 6, a sequence compleType: ApplicationFiled: May 27, 2015Publication date: August 3, 2017Inventors: Christine ROUZIOUX, Jean-Christophe PLANTIER, Véronique AVETAND-FENOEL, Florence DAMOND, Marie GUEDIN, Diane DESCAMPS
-
Publication number: 20160130652Abstract: The invention relates to the diagnosis of HIV-associated nephropathy (HIVAN) based on determining the expression level of HIV nucleic acids (HIV RNA and/or DNA) in combination with the renal function of a patient. The invention also relates to a method for distinguishing between HIVAN and non-HIVAN kidney disease in a patient based on the expression level of urinary HIV nucleic acids.Type: ApplicationFiled: May 28, 2014Publication date: May 12, 2016Inventors: Guillaume CANAUD, Fabiola TERZI, Christine ROUZIOUX
-
Patent number: 7341731Abstract: The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.Type: GrantFiled: June 27, 2002Date of Patent: March 11, 2008Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 7232654Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: September 19, 1994Date of Patent: June 19, 2007Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jean-Claude Chermann, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7217508Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: February 22, 1988Date of Patent: May 15, 2007Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Simon Wain-Hobson, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7205102Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: June 7, 1995Date of Patent: April 17, 2007Assignees: Institut Pasteur, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Jean-Claude Chermann, Francoise Barre-Sinoussi, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7122188Abstract: This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.Type: GrantFiled: May 26, 1993Date of Patent: October 17, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Bruil, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
-
Patent number: 7115363Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.Type: GrantFiled: June 6, 1995Date of Patent: October 3, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6664041Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.Type: GrantFiled: May 23, 2001Date of Patent: December 16, 2003Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6627395Abstract: The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.Type: GrantFiled: June 6, 1995Date of Patent: September 30, 2003Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Publication number: 20030170658Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.Type: ApplicationFiled: June 27, 2002Publication date: September 11, 2003Applicant: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6600023Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.Type: GrantFiled: February 18, 1993Date of Patent: July 29, 2003Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6428952Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.Type: GrantFiled: April 19, 1995Date of Patent: August 6, 2002Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, G. Sarngadharan
-
Patent number: 6395495Abstract: The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.Type: GrantFiled: November 10, 1999Date of Patent: May 28, 2002Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Robert C Gallo, Mikulas Popovic, Mangalasseril G Sarngadhar, Claudine Axler-Blin, Solange Chamaret
-
Publication number: 20020051967Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.Type: ApplicationFiled: May 23, 2001Publication date: May 2, 2002Applicant: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6265149Abstract: The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.Type: GrantFiled: June 6, 1995Date of Patent: July 24, 2001Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6037165Abstract: Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.Type: GrantFiled: June 6, 1995Date of Patent: March 14, 2000Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Fran.cedilla.ois Clavel, Mireille Guyader, Pierre Sonigo, Fran.cedilla.oise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama